Drug Y

Drug Y (also known as BCH-201) is a clinical-stage therapeutic candidate being developed by BioConvergent Health for the treatment of thrombocytopenia in patients with low-risk Myelodysplastic Syndrome (MDS). Currently in Phase 2 development with an FDA-aligned clinical program, Drug Y has demonstrated clinical proof-of-concept (POC) in its primary indication. The asset was acquired through an exclusive worldwide license and is part of BioConvergent Health's broader pipeline that integrates pharmacological agents with energy-based devices (such as radiation and ultrasound) and cell therapies. While specific molecular details are proprietary and protected under non-disclosure agreements, Drug Y is characterized as a thrombopoietin receptor (TPO-R) agonist. In addition to its use in MDS, Drug Y is being evaluated in Phase 1b/2 combination trials with 'Drug X' and radiation therapy for the treatment of other unspecified cancers.